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Abstract
The international liver glycogen storage disease (GSD) priority setting partnership
(IGSDPSP) was established to identify the top research priorities in this area. The
multiphase methodology followed the principles of the James Lind Alliance (JLA)
guidebook. An international scoping survey in seven languages was distributed to
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patients, carers, and healthcare professionals to gather uncertainties, which were
consolidated into summary questions. The existing literature was reviewed to
ensure that the summary questions had not yet been answered. A second survey asked
responders to prioritize these summary questions. A final shortlist of 22 questions was
discussed during an international multi-stakeholder workshop, and a consensus was
reached on the top 11 priorities using an adapted nominal group technique.In the first
survey, a total of 1388 questions were identified from 763 responders from 58 coun-
tries. These original uncertainties were refined into 72 summary questions for a second
prioritization survey. In total 562 responders from 58 countries answered the second
survey. From the second survey, the top 10 for patients, carers and healthcare profes-
sionals was identified and this shortlist of 22 questions was taken to the final workshop.
During the final workshop, participants identified the worldwide top 11 research priori-
ties for liver GSD. In addition, a top three research priorities per liver GSD subtype
was identified.This unique priority setting partnership is the first international, multilin-
gual priority setting partnership focusing on ultra-rare diseases. This process provides a
valuable resource for researchers and funding agencies to foster interdisciplinary and
transnational research projects with a clear benefit for patients.
KEYWORD S
caregivers, James Lind Alliance, liver glycogen storage diseases, patient participation, priority setting
partnership, rare diseases, research, research priorities
1 | INTRODUCTION
Liver glycogen storage diseases (GSD) are ultra-rare diseases,
among the oldest known inborn errors of metabolism described
in literature, and classified according to the protein deficiency
and the organ distribution.1 Liver GSD subtypes include GSD
0, Ia, Ib, III, IV, VI, IX, and XI, and classical clinical presenta-
tions of patients include severe fasting intolerance, growth fail-
ure, and hepatomegaly. Biochemically, liver GSD is associated
with hypoglycemia, hyperlactatemia, increased liver enzymes,
and hyperlipidemia. Long-term complications include liver
adenomas, nephropathy, cardiomyopathy, and severe muscle
symptoms. Strict dietary management is the cornerstone of
management to maintain normal blood glucose concentrations,
to suppress secondary metabolic derangements and to prevent
long-term complications.2 Although we now understand details
of the diseases that we did not some decades ago, we are still
missing important information in many areas of the field.
The international GSD community has a longstanding tradi-
tion of involving patient representatives in directing healthcare
and research.3,4 However, there are discrepancies between
questions considered relevant by patients, carers, and healthcare
professionals, and the research performed in rare diseases.5 The
James Lind Alliance (JLA) was set up in 2004 to facilitate part-
nerships between patients, carers, and healthcare professionals
and help to identify research priorities. The JLA developed a
process for identifying these research uncertainties that are
important to either patients, carers, and/or clinicians. In a
“priority setting partnership (PSP),” the JLA methodology
works equally with these stakeholders to prioritize research
uncertainties to guide future funding and investments.6 The
JLA methodology has been used in almost 100 other areas of
healthcare and has shown differences in research priorities
between on one side researchers and on the other patients,
carers, and healthcare professionals (http://www.jla.nihr.ac.uk/
priority-setting-partnerships/).
To address research priorities of direct relevance and
potential benefit to liver GSD patients, carers, and the
treating healthcare providers, the international liver glycogen
storage disease priority setting partnership (IGSDPSP) was
initiated on 11 November 2016. The IGSDPSP has been the
first international, multilingual PSP to identify and prioritize
uncertainties in a group of ultra-rare diseases. Here, we
report the process and outcomes of this partnership including
the top 11 research priorities in the field of liver GSD,
agreed upon by patients, carers, and clinicians.
2 | METHODS
The Medical Ethical Committee of the University Medical Cen-
tre Groningen confirmed that the Law on Medical Scientific
Research involving Human Beings (WMO) did not apply to
the IGSDPSP (METc 2017/386).
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For 30 months, the multiphase methodology followed the
principles of the JLA guidebook,7 as depicted in Figure 1 and on
our website (http://igsdpsp.com). Prior to the start of the PSP,
key challenges were determined in the readiness questionnaire
(File S1). After the senior author (T.D.) reaching out to the JLA,
potential partners such as patients, individuals that care for
patients (carers), patients/carers active in national patient organi-
zations (patient representatives), and healthcare professionals
FIGURE 1 Flow chart of the international liver GSD priority setting partnership process
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(physicians, dieticians, nurses) were contacted and informed of
the establishment and aims of the IGSDPSP. People who
showed interest were invited to attend and participate in the
initial awareness meeting and the first steering group meeting
during the International GSD conference in Groningen (the
Netherlands) held on 15 to 17 June 2017. Before the initial
awareness meeting, this open invitation was repeated during an
oral presentation by the JLA advisor (K.C.) at one of the ple-
nary sessions. The steering group had consisted of 14 members
from 12 countries of whom some represented more than one
stakeholder: 10 carers or patients, 9 healthcare professionals
(7 physicians, 1 nurse, 1 dietician), and 8 representatives of
patient organizations. The group was chaired and facilitated by
K.C. and two information specialists (F.P., W.F.B.), who
analysed and categorized the raw data from the surveys. In
total, 11 telephone conferences and 3 in-person meetings took
place. Phases of the process were closelymonitored and guided
by the steering group. The JLA Priority Setting Partnership
four-step process was followed, involving (a) gathering uncer-
tainties, (b) formulating summary questions, (c) interim priority
setting, and (d) final priority setting (Figure 1).
2.1 | Gathering uncertainties
An online international scoping survey to gather uncertainties
was designed via SurveyMonkey (a digital platform for design-
ing and distributing surveys) and underwent pretesting and
refinement with the steering group and selected members of the
liver GSD community (File S2). Afterwards, the survey was
translated into seven languages (Dutch, English, French, Ger-
man, Italian, Portuguese, and Spanish) by native speakers from
the steering group. From 1 October to 14 December 2017, this
first survey was distributed to patients, carers, and healthcare
professionals by multiple partner organizations, such as patient
organizations, professional networks, and individual patients,
carers, and healthcare professionals. The survey requested up to
three answers to the question: “What are your questions on the
care and/or management of liver Glycogen Storage Disease?”
Furthermore, basic demographic data were collected (age of
patient[s], role, type of liver GSD, country of origin/work). The
collected uncertainties were categorized qualitatively based on
the UK Clinical Research Collaboration Health Classification
System (diagnosis, prevention, prognosis, education, health ser-
vices, social care, self-management, and treatment) and further
subcategorized according to the specific topic. Questions con-
sidered to be “out-of-scope” were removed at this stage after
agreement by the steering group.
2.2 | Formulating summary questions
The categorized uncertainties were collected into a small
number of summary questions during the second in-person
steering group meeting at the Scandinavian bi-annual patient
meeting for patients with liver GSD (SAGSD) in Ängelholm
(Sweden) on 28 and 29 April 2018. The process was over-
seen by JLA Advisor (K.C.), emphasizing that the data
should be treated with neutrality and transparency. An exten-
sive literature search was performed to ensure that these
summary questions had not been answered. The search
focused on information from available reviews, guidelines,
and a PubMed search strategy containing Medical Subject
Heading (MESH) terms from each summary question.
2.3 | Interim priority setting
A second online prioritization survey was designed via
SurveyMonkey, refined with the steering group and translated
into seven languages (File S3). From 19 March to 27 April
2019, the prioritization survey was launched and asked respon-
dents to prioritize the summary questions. The distribution was
performed via the same partner organizations used for the first
survey and through participants from the first survey who sent
their contact details. Responders were asked in a two-step pro-
cess to choose their top 10 research questions on the care
and/or management of liver GSD. Again, basic demographic
data were collected (age of patient[s], role, type of liver GSD,
country of origin/work). Questions were ranked ordinally and
if two questions ranked equally, the joint rank was given. The
top 10 questions for patients, carers, and healthcare profes-
sionals were selected separately for the final prioritization
workshop to include priorities for each group, accounted for
discrepancies between groups and illustrated the importance of
shared-decision taking at the final workshop.
2.4 | Final priority setting
Via an open call on the IGSDPSP website, social media, and
by steering group members (including D.A.W. and T.D.),
people with liver GSD, carers, and healthcare professionals
were suggested as participants for the final priority setting
workshop at the Selbsthilfegruppe Glykogenose Deutsch-
land e.V. in Duderstadt (Germany) on 24 May 2019. The
selection and invitation was overseen by the independent
JLA advisor (K.C.). Participants who initiate research, and
thus already had the possibility to influence the research
agenda, were excluded from participation in the final work-
shop, at which D.A.W. and T.D. were only observers and
did not participate. Furthermore, all participants in the final
workshop (Table 1) were fully reimbursed for their travel
and accommodation costs to reduce economical and geo-
graphical bias. Participants were selected to represent the
international liver GSD community and the GSD subtypes.
Participants declared that they did not have any conflict of
interest that might influence the priority setting process. The
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workshop was guided by three trained JLA advisors (includ-
ing K.C.) using an adapted nominal group technique.7,8 Par-
ticipants were divided in three smaller groups comprising of
different stakeholders and ranked questions in two rounds.
Between rounds, the average ranking of the questions were
determined by F.P. and K.C., after which the questions were
presented in the ranked order in the second round. In a final
plenary session, the participants were able to comment on
the ranking and were able to revise the order one final time.
3 | RESULTS
Table 1 presents the demographics for the responders from
both surveys and the final workshop participants.
3.1 | Gathering uncertainties
In the first survey, a total of 1388 questions were identified
from 763 responders from 58 countries.
3.2 | Formulating summary questions
The questions identified through the first survey were cate-
gorized by the information specialists (F.P. and W.F.B.).
Afterwards, each individual question was defined as in-
scope or out-of-scope. Of the 1388 questions, 505 were
deemed out-of-scope by the information specialists and the
steering group (File S4). During the SAGSD, the steering
group reconvened and formulated 72 summary questions
from the remaining individual in-scope questions in three
groups (File S5 and S6). Of these out-of-scope questions,
the steering group made sure that the topics raised were cov-
ered in the summary questions. Each group included at least
a patient or carer, healthcare professional and a patient repre-
sentative. Afterwards, the evidence check ascertained that
the summary questions were unanswered.
3.3 | Interim priority setting
Of these 72 summary questions, the top 10 for each stake-
holder group (patients, carers, and healthcare professionals)
TABLE 2 Top 11 priorities for research in liver GSD, in rank order of priority
Listed rank after the second survey
Rank Priority Patients Carers HCP
1 What are the best options (eg, gene therapy or enzyme replacement
therapy) for achieving sufficient amount of working enzyme in patients
with liver GSD?
3J 6J 12J
2 Can consensus guidelines (for management) be achieved for patients with
liver GSD?
71 58J 8J
3 How should optimal metabolic control both clinically and biochemically
(like lactate, ketones, and/or lipids) be achieved in liver GSD?
20J 32J 5J
4 How should sickness and emergency situations be managed for patients
with liver GSD?
9J 7 18
5 What is the best way to start dietary treatment, finding the optimal doses,
and to administer the diet for patients with liver GSD?
34J 37J 10J
6 How can existing cornstarch preparations be modified or alternative
treatments be implemented that are easier to administer and/or keep
blood sugar levels more stable for patients with liver GSD?
9J 4 4
7 What is the role for new methods for monitoring metabolic control (like
noninvasive continuous glucose and lactate measurements, new
biomarkers) for patients with liver GSD?
40J 24J 8J
8 How to manage diet regimen in relation to "before, during and after"
physical exercise (sport, playing) for patients with liver GSD?
5J 3 14
9 What are the long-term complications (liver, renal, gut) of a diet rich in
uncooked cornstarch and/or high protein and should the diet be adjusted
to prevent complications in liver GSD?
9J 1 3
10 What are the risks and benefits of different options for overnight treatment
for patients with liver GSD and how can we maximize safety?
48J 22J 10J
11 How to prevent and/or treat muscle problems in patients with liver GSD? 2 24J 22J
Abbreviations: HCP, healthcare professional; J, joint rank.
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GSD 0 1 23J What are the consequences of consumption of alcohol and drugs for patients with liver Glycogen
Storage Disease?
2 29J What (laboratory) testing and with which frequency is optimal for monitoring patients with liver
Glycogen Storage Disease?
3 5 How to manage diet regimen in relation to “before, during and after” physical exercise (sport,
playing) for patients with liver Glycogen Storage Disease?
GSD Ia 1 2 What are the risks and benefits of gene therapy for patients with liver Glycogen Storage
Disease?
2 1 What are the long-term complications (liver, renal, gut) of a diet rich in uncooked cornstarch
and/or high protein and should the diet be adjusted to prevent complications in liver Glycogen
Storage Disease?
3 4 What are the best options (eg, gene therapy or enzyme replacement therapy) for achieving
sufficient amount of working enzyme in patients with liver Glycogen Storage Disease?
GSD Ib 1 41 What is the best therapy for neutropenia and infections (ie, G-CSF or alternatives considering
outcomes), complications and side effects (ie, bone pain) in patients with Glycogen Storage
Disease Type Ib (or Ia)?
2 50J What is the optimal therapy (Modulen or alternatives) for inflammatory bowel disease (IBD) and
acute flares in patients with Glycogen Storage Disease Type Ib?
3 16 How to better prevent and/or treat intestinal problems in patients with liver Glycogen Storage
Disease?
GSD III 1 10 How to prevent and/or treat muscle problems in patients with liver Glycogen Storage Disease?
2 20 What are the effects of different kinds of Ketogenic Diet in patients with Glycogen Storage
Disease Type III?
3 2 What are the risks and benefits of gene therapy for patients with liver Glycogen Storage
Disease?
GSD IV 1 11 How is the (natural) progression of liver Glycogen Storage Disease at different stages of life?
2 23J When should liver transplantation be considered in patients with liver Glycogen Storage Disease
and what are the (dis)advantages and long-term outcomes?
3 6J What is the needed restriction of lactose, fructose or saccharose in different types of liver
Glycogen Storage Disease?
GSD VI 1 43 How do body changes throughout life impact blood sugars in patients with liver Glycogen
Storage Disease?
2 23J When should liver transplantation be considered in patients with liver Glycogen Storage Disease
and what are the (dis)advantages and long-term outcomes?
3 50J How can we personalize treatment for patients with liver Glycogen Storage Disease?
GSD IX 1 1 What are the long-term complications (liver, renal, gut) of a diet rich in uncooked cornstarch
and/or high protein and should the diet be adjusted to prevent complications in liver Glycogen
Storage Disease?
2 6J What is the needed restriction of lactose, fructose or saccharose in different types of liver
Glycogen Storage Disease?
3 5 How to manage diet regimen in relation to “before, during and after” physical exercise (sport,
playing) for patients with liver Glycogen Storage Disease?
GSD XI 1 39 How can all healthcare providers involved (including experts) contribute to shared care for
individual patients with liver Glycogen Storage Disease?
2 3 How can existing cornstarch preparations be modified or alternative treatments be implemented
that are easier to administer and/or keep blood sugar levels more stable for patients with liver
Glycogen Storage Disease?
(Continues)
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were identified and taken to the final priority setting workshop,
resulting in a shortlist of 22 summary questions (File S6).
3.4 | Final priority setting
The final workshop participants agreed upon the top 11 priori-
ties for liver GSD together via open and respectful discussions
(Table 2). First, the participants agreed on the importance of
including questions on subtypes of liver GSD and voted unan-
imously that an 11th question should be added on the preven-
tion of muscle problems—an important topic for GSD IIIa.
Second, the steering group and final workshop participants
decided to present the top 3 research priorities for each sub-
type, in addition to the general top 11 research priorities. The
top three research priorities for GSD subtypes was based on
the results from the second survey to represent the ultra-rare
subtypes of liver GSD (ie, GSD 0, IV, VI, XI) (Table 3). If
there were multiple questions that had a joint rank in the top
3, we prioritized the questions that were highest in the overall
ranking after the second survey. Third, the final workshop
participants emphasized that the research question on quality
of life should not be a single priority, but they acknowledged
quality of life as an overarching priority in liver GSD.
4 | DISCUSSION
We describe here the first international, multilingual PSP focus-
ing on a group of ultra-rare diseases. By involving patients,
carers, and healthcare professionals from 73 countries, we have
identified the top 11 research priorities for liver GSD (Table 2).
In addition, priorities have been formulated for subtypes of liver
GSD (Table 3). The majority of the top research priorities are
relevant healthcare topics for many other inborn errors of
metabolism and rare diseases in general. Our approach
conveys a message towards researchers to invent new
therapies and obtain worldwide management consensus
by the different stakeholders, for example, patients, carers,
and healthcare professionals.
With our approach—the multiphase PSP methodology
following the JLA principles—patients, carers, and healthcare
professionals jointly agreed on the top 11 research priorities.
It is important to note that these priorities did not match those
deemed by the professionals alone. Healthcare professionals
prioritized, amongst other topics, metabolic control, new
methods of metabolic monitoring and the role of dietary
medium-chain triglycerides. Patients and carers emphasized
the importance of natural progression of disease and compli-
cations. Additionally, we were able to determine the top three
research priorities per subtype of liver GSD (Table 3).
Research priorities for GSD Ia focus on the gene therapy trial,
whereas for GSD Ib and GSD III, on prevention of complica-
tions. Top priorities for the ketotic GSD subtypes 0, VI, and
IX concern dietary restrictions and personalised treatment,
and for the rarest GSD subtypes, that is, IV and XI, natural
progression and treatment.
In 2012 and 2018 respectively, PSPs for diabetes mellitus
(DM) type I9 and type II10 led to the identification of top
10 priorities. Given the existing similarities (in terms of
monitoring glucose homeostasis, organization of health care,
long-term outcome) and differences (rarity, funding opportu-
nities for research and reimbursement of basic health care
for individual patients) between DM and liver GSD, it is
interesting to compare the outcomes of the PSPs for these
disorders. Similar to the top priority identified for DM type
II, the top priority for liver GSD focuses on curing or revers-
ing the condition. Furthermore, for DM Type I, the top prior-
ity is about the accurate monitoring of blood glucose
concentrations, which is also mentioned twice in the top
11 (rank 3 and 7) research priorities for liver GSD. The simi-
larities between the research priorities provide opportunities
for shared research and healthcare projects that transcend the







3 1 What are the long-term complications (liver, renal, gut) of a diet rich in uncooked cornstarch




1 3 How can existing cornstarch preparations be modified or alternative treatments be implemented
that are easier to administer and/or keep blood sugar levels more stable for patients with liver
Glycogen Storage Disease?
2 5 How to manage diet regimen in relation to “before, during and after” physical exercise (sport,
playing) for patients with liver Glycogen Storage Disease?
3 10 How to prevent and/or treat muscle problems in patients with liver Glycogen Storage Disease?
Abbreviation: J, joint rank.
aRank after the second prioritization survey, but before the final prioritization workshop.
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Key challenges and limitations of our study were fore-
seen in the readiness questionnaire formulated at the start of
the PSP (File S1). First, whereas in other PSPs, steering
group members are from one country (ie, United Kingdom),
our steering group members are from 12 countries,
highlighting language differences both among IGSDPSP
steering group members (50% were non-native English
speakers) and survey responders. Second, the surveys on
liver GSD were self-reported and therefore may over-
represent more severely affected patients. Third, although
the JLA methodology strives to be transparent, open, and
methodologically defensible, the approach has remained
pragmatical and built upon the responses of end users. The
qualitative analysis of the prioritization process is
influenced by differences in response rates between individ-
uals, countries, and cultures (Table 1). To reduce potential
bias as much as possible, we widely distributed the surveys
via professional and patient networks including social
media, not limiting them to GSD patient organization mem-
bers. Furthermore, both the steering group and the final
workshop participants originated from multiple countries
from Europe, North America, and South America. Patients,
carers, and healthcare professionals have been consulted
extensively throughout the entire process and the priorities
are a result from a consensus decision taking process.
Since several stakeholders, including patients, carers, patient
representatives, healthcare professionals, researchers, and
funders, will be involved in answering the top priorities, we
think it is important to inform them on the results of the PSP.
To assure this, the steering group discussed the strategy for dis-
semination to reach these stakeholders after the final workshop.
The strategy included this detailed scientific manuscript, a lay
report, a social media and website campaign, press-releases via
patient organizations and channels from the JLA, and planned
activities at the International GSD Conference in Porto Alegre,
Brazil, from 14 to 16 November 2019. The steering group will
continue to serve as a platform to disseminate the results from
our PSP to a broader audience and to both monitor and share
information on future research projects that result from these
top priorities. In the future, funding for these research priorities
should be addressed by stakeholders in national and interna-
tional grant applications for basic, translational, clinical, and
public health research projects.
Currently, global funding in the biomedical research field
involves billions of dollars and millions of people.11 In this land-
scape, eminent scientists who obtain funding determine the
course of research and this has not changed in the past
decades.12,13 Ideally decisions about research funding should take
patients, carers, and healthcare professionals into consideration,11
but often they are not involved in the choice, design, performance,
analysis, and dissemination of research.
Since liver GSD is a group of inborn errors of metabolism
with extremely low prevalence, we consider our IGSDPSP as
a proof of principle for ensuring stakeholder participation, and
patient empowerment in rare and ultra-rare diseases, in partic-
ular within the metabolic community. In these areas, more
than in others, healthcare and research need to be intimately
connected with all stakeholders.14 The IGSDPSP shows the
importance to formulate research priorities together with
patients, carers and healthcare professionals to share each
other's point of view. We believe that our approach is essen-
tial for defining research priorities and for advancing research
and treatment in rare diseases.
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